RNA Sequencing Market Size, Share, Industry, Forecast and outlook 2026-2033

RNA Sequencing Market Size

RNA Sequencing Market reached US$ 3,712.4 million in 2025 and is expected to reach US$ 17,148.6 million by 2033, growing at a CAGR of 22.7% during the forecast period 2026-2033.

RNA Sequencing Market Scope

RNA Sequencing Market Dynamics and Trends

The RNA sequencing market is expected to grow due to increase in adoption of personalized medicine due to decrease in cost of sequencing, increased utility in predictive biomarkers and therapeutic response research and significant external funding for executing research and development .

Less cost of sequencing and effectiveness in the treatment of cancer will drive the market growth

The global insistence for RNA sequencing over traditional technologies has proven to be the industry's driving factor. RNA sequencing has greater sensitivity for genes expressed at low or very high levels and a greater dynamic range of expression levels over which transcripts can be detected (>8000-fold range). In addition, compared to previous conventional technologies and recent advances in the RNA-Seq workflow, from sample preparation to library construction to data analysis, it provides insight into a cell's transcriptome.

Furthermore, the effectiveness of RNA sequencing in the current COVID-19 situation has resulted in many top industries adopting these technologies, resulting in their growth. Its effectiveness in treating many diseases, including cancer, has improved the overall healthcare system.

Developing countries' governments and private sectors have invested in their research and development sectors and RNA sequencing programs to gain a thorough understanding of genetics and diseases. Many government organizations have taken an active role in the sequencing program to find better ways to treat cancer and other diseases. As a result of this widespread support, several new entrants have entered the market, and numerous RNA sequencing projects have been launched, contributing to the industry's overall growth and providing opportunities for key players.

The lower cost of genome sequencing has resulted in broad acceptance of these techniques, positively influencing the adoption of RNA sequencing product lines. Furthermore, government groups have contributed major financing for technological developments, including RNA sequencing. RNA sequencing also aids in the discovery of differentially expressed genes, allowing numerous researchers to identify up-and down-regulated genes linked to various malignancies quickly. This contributes to the growth of the global RNA sequencing market.

Lack of funding and scarcity of skilled professionals is likely to hamper the market growth

In developing economies, research and development spending primarily rely on funding from outside sources. Although governments and private bodies try to fund research programs, many research firms and academic institutes face budget constraints. They cannot afford advanced and high-priced equipment and technologies, which harms the growth of these industries and their expansion in developing countries. RNA-based mappings rely on cDNA synthesis, which is problematic for short-lived transcripts like primary microRNAs, the efficiency of which is determined by RNA sequence and structure. Furthermore, there is a scarcity of skilled professionals in this industry, further impeding its growth. As a result, interpreting complex data takes time, and researchers face challenges, resulting in slow industry growth.

RNA Sequencing Market Geographical Share

North America region holds the largest market share of global RNA sequencing   market

The RNA sequencing market in North America is the largest in the world. The RNA sequencing platforms and consumable sector hold the most market share, and the industry's increasing rise in North America can be attributed to the market's constant technological improvements. The presence of major players such as Illumina in the region and increased use of techniques such as ion semiconductor sequencing are moving the RNA sequencing market in North America forward.

RNA Sequencing Companies and Competitive Landscape

The RNA sequencing market is highly competitive with presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include Roche Holding AG,Agilent Technologies, Illumina Inc,Therma Fisher Scientific ,Macrogen Inc, Beijing Genomics Institute, Qiagen, DNASTAR, GATC Biotech AG, Pacific Biosciences of California Inc. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the RNA sequencing market globally. For instance May 2021, PerkinElmer, Inc. has declared the launch of two RUO solutions: the P Kamp TM Variant Detect TM SARS-CoV-2 RT-PCR Assay and the NEXTFLEX Variant-Seq TM SARS-CoV-2 Kit based on Next-Generation Sequencing. Laboratories can use these assays to detect genomic changes linked to SARS-CoV-2 variants using nucleic acid isolated from previously tested positive samples. Clinical laboratories and the healthcare community have been warned about SARS-CoV-2 viral alterations by public health agencies such as the US FDA.

Recent Developments

• April 2026 – Illumina expands high-throughput RNA sequencing capabilities for multiomics research
  Illumina Inc. introduced enhanced sequencing workflows and AI-driven bioinformatics tools designed to accelerate transcriptomics, single-cell RNA sequencing, and precision medicine research applications.
• April 2026 – Roche advances integrated sequencing and companion diagnostics strategy
  Roche Holding AG strengthened its genomics and transcriptomics portfolio through expanded sequencing automation and AI-enabled data interpretation tools supporting oncology and clinical research applications.
• March 2026 – Thermo Fisher Scientific launches next-generation RNA sequencing workflow solutions
  Thermo Fisher Scientific introduced upgraded RNA library preparation kits, automation systems, and cloud-based analysis platforms aimed at improving speed and accuracy in transcriptomics research.
• March 2026 – QIAGEN expands bioinformatics and sample preparation tools for transcriptomics
  QIAGEN launched advanced RNA extraction and sequencing analysis solutions supporting biomarker discovery, disease pathway analysis, and precision medicine research initiatives globally.
• February 2026 – BGI strengthens large-scale transcriptomics and clinical genomics initiatives
  Beijing Genomics Institute expanded RNA sequencing service capabilities and high-throughput genomic analysis infrastructure supporting population-scale research and clinical applications.
• February 2026 – Agilent advances automated sample preparation for RNA sequencing laboratories
  Agilent Technologies introduced new automation platforms and quality control solutions designed to improve RNA sequencing workflow reproducibility and laboratory efficiency.

• January 2026 – Macrogen expands global sequencing services and AI-driven genomic analysis
  Macrogen Inc. strengthened international sequencing operations with expanded transcriptomics services and AI-supported genomic data analysis platforms for pharmaceutical and academic research customers.

Roche Holding AG

Overview: Roche Holding AG is a pharmaceutical research and development company. It operates in two divisions: pharmaceuticals and diagnostics. The Pharmaceutical division includes companies like Roche Pharmaceuticals and Chuga. The Diagnostic division comprises four business units: centralized and point-of-care solutions, molecular diagnostics, tissue diagnostics, and diabetes care.

Product Portfolio:

AVENIO Edge System:  The AVENIO Edge System is a pre-analytical plan for target enrichment, sequencing library preparation and quantification processes that provide integrated, end-to-end control and high-quality findings.